DUBLIN, September 22, 2021--(BUSINESS WIRE)--The "Continuous and Semi-Continuous Bioprocessing Market by Type of Manufacturer, Company Size, Scale of Operation, Stage of Bioprocess, Geographical Regions: Industry Trends and Global Forecasts, 2021-2030" report has been added to ResearchAndMarkets.com's offering.
This report features an extensive study on the companies having continuous and semi-continuous bioprocessing capabilities. The study underlines an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.
For years, the batch and fed-batch processing technique has been the only available solution for biomanufacturing. However, this method is plagued with several shortcomings, such as process inefficiencies, high risk of human errors and low production speeds. Modern biopharmaceuticals demand faster, and more efficient technologies, preferably with seamless transition into succeeding steps; the primary goal, in this regard, being the preservation of sterility. In other words, a continuous bioprocessing approach is better suited to the needs of the aseptic manufacturing paradigm that is required for biologics. In this context, the introduction of perfusion bioreactors in the late 1980s was a revolutionary development within the industry.
Presently, there are multiple available technologies that are capable of supporting continuous downstream (including clarification / centrifugation, filtration, and chromatography steps) and upstream bioprocesses (which include cell line development and other pre-fermentation steps). A significant number of biopharmaceutical companies, especially certain big pharma players and large contract manufacturing service providers, claim to have already adopted, or are considering installing, continuous bioprocessing technologies, such as perfusion bioreactors, continuous chromatography and continuous filtration equipment. Continuous flow systems have been proven to address a number of challenges associated with traditional bioprocessing; for instance, they facilitate the lowering of manufacturing costs (by 60%), reduction in buffer use (by 30-50%), optimization of resin consumption (by 70%) in chromatography columns, reduction in product change over time (by 90%), improvement of product consistency across different batches (by 50%), minimizing facility footprints (by 50-70%), reduction in operating expenditure (by 90%) and seamless scale up. All the aforementioned advantages eventually serve to improve overall productivity.
The current focus of the users of this novel technology is primarily on upgrading individual operations to the continuous mode; as indicated earlier, some companies have already established bioprocessing lines with multiple continuous processes. Cost, (end product) quality, processing speed and operational flexibility are some of the primary driving factors of the gradual shift to continuous bioprocessing. The COVID-19 pandemic has also contributed to accelerating the adoption of continuous flow systems. Some of the existing challenges in this field include complexities related to defining continuous processes (especially those upstream to the fermentation step), and aligning the available equipment to operate as per current GMP requirements. Although an end-to-end continuous bioproduction line is still several years away, we believe that the opportunity for both innovators and service providers engaged in this domain is likely to grow in the foreseen future.
Avid Bioservices (formerly Peregrine Pharmaceuticals)
Boehringer Ingelheim BioXcellence
Changchun High & New Technology
Cell and Gene Therapy Catapult
Cell Culture Company
Centre for Process Innovation (CPI)
Engage Therapeutics (Acquired by UCB Pharma)
FUJIFILM Diosynth Biotechnologies
Gallus BioPharmaceuticals (Acquired by Patheon)
Global BioTherapeutics (GBT)
And Many More Companies!
Key Questions Answered
Which are the leading contract manufacturers offering expertise in continuous bioprocessing?
Which are the leading innovators / drug developers with expertise in continuous bioprocessing?
In which regions are majority of the continuous and semi-continuous bioprocessing facilities located?
What is the likely cost saving potential of continuous and semi-continuous bioprocessing technology?
What is the currently installed global capacity for continuous and semi-continuous bioprocessing?
How is the current and future market opportunity likely to be distributed across key market segments?
Key Topics Covered:
2. EXECUTIVE SUMMARY
4. MARKET LANDSCAPE
5. CONTINUOUS BIOPROCESSING IN NORTH AMERICA: COMPANY PROFILES
6. CONTINUOUS BIOPROCESSING IN EUROPE: COMPANY PROFILES
7. CONTINUOUS BIOPROCESSING IN ASIA-PACIFIC: COMPANY PROFILES
8. INITIATIVES OF COMPANIES WITH IN-HOUSE CONTINUOUS BIOPROCESSING CAPABILITIES
9. CONTINUOUS MANUFACTURING EQUIPMENT FOR BIOLOGICS: MARKET LANDSCAPE
10. COST SAVING ANALYSIS
11. CAPACITY ANALYSIS
12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14. EXECUTIVE INSIGHTS
15. APPENDIX 1: TABULATED DATA
16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
For more information about this report visit https://www.researchandmarkets.com/r/9sgw35
View source version on businesswire.com: https://www.businesswire.com/news/home/20210922005732/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900